{"transactions":[{"id":1693243,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-01-03T16:44:56.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 1, 2023, the Reporting Person was granted 108,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 1, 2023, the Reporting Person was granted 108,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":81000,"derivative":{"underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-24-000416","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919124000416/doc4.xml","form_type":"4"}},{"id":1693242,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Common Stock","published_at":"2024-01-03T16:44:56.000Z","date":"2024-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":9125,"price":1.05,"value":9581.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":41813,"source":{"system":"sec-edgar","filing":"0001209191-24-000416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919124000416/doc4.xml","form_type":"4"}},{"id":1693241,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Common Stock","published_at":"2024-01-03T16:44:56.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":true,"shares":27000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":50938,"source":{"system":"sec-edgar","filing":"0001209191-24-000416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919124000416/doc4.xml","form_type":"4"}},{"id":1816629,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Restricted Stock Units","published_at":"2023-08-03T16:24:53.000Z","date":"2023-08-01","kind":"exercise","planned":false,"acquired":false,"shares":15575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":46725,"derivative":{"underlying":"Common Stock","underlying_shares":15575},"source":{"system":"sec-edgar","filing":"0001209191-23-044445","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919123044445/doc4.xml","form_type":"4"}},{"id":1816628,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Common Stock","published_at":"2023-08-03T16:24:53.000Z","date":"2023-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":4437,"price":9.81,"value":43526.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":23938,"source":{"system":"sec-edgar","filing":"0001209191-23-044445","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919123044445/doc4.xml","form_type":"4"}},{"id":1816627,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Common Stock","published_at":"2023-08-03T16:24:53.000Z","date":"2023-08-01","kind":"exercise","planned":false,"acquired":true,"shares":15575,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":28375,"source":{"system":"sec-edgar","filing":"0001209191-23-044445","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919123044445/doc4.xml","form_type":"4"}},{"id":1947558,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Common Stock","published_at":"2023-03-17T17:03:45.000Z","date":"2023-03-17","kind":"purchase","acquired":true,"shares":6300,"price":7.8623,"value":49532.49,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $7.86 to $7.8641, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":12800,"source":{"system":"sec-edgar","filing":"0001209191-23-019743","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919123019743/doc4.xml","form_type":"4"}},{"id":1961272,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Common Stock","published_at":"2023-03-09T17:56:40.000Z","date":"2023-03-09","kind":"purchase","acquired":true,"shares":6500,"price":7.735,"value":50277.5,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001209191-23-017626","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919123017626/doc4.xml","form_type":"4"}},{"id":2033436,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Restricted Stock Units","published_at":"2023-02-03T17:04:16.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":108000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":108000,"derivative":{"underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001209191-23-007013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919123007013/doc4.xml","form_type":"4"}},{"id":2033435,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-02-03T17:04:16.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":378000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":378000,"derivative":{"exercise_price":16.97,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":378000},"source":{"system":"sec-edgar","filing":"0001209191-23-007013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919123007013/doc4.xml","form_type":"4"}},{"id":2197892,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and COO"}}],"security":"Restricted Stock Units","published_at":"2022-08-02T17:10:47.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":62300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting\nPerson's continuous service with the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting\nPerson's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":62300,"derivative":{"underlying":"Common Stock","underlying_shares":62300},"source":{"system":"sec-edgar","filing":"0001209191-22-043928","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919122043928/doc4.xml","form_type":"4"}},{"id":2197891,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres and COO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-02T17:10:47.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":217800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":217800,"derivative":{"exercise_price":13.62,"expiration_date":"2032-07-31","underlying":"Common Stock","underlying_shares":217800},"source":{"system":"sec-edgar","filing":"0001209191-22-043928","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875875/000120919122043928/doc4.xml","form_type":"4"}},{"id":2338160,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research & Development"}}],"security":"Employee Performance Restricted Stock Unit","published_at":"2022-03-11T16:12:30.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":15200,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001628280-22-005892","document":"wf-form4_164703313587429.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005892/wf-form4_164703313587429.xml","form_type":"4"}},{"id":2338159,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research & Development"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-11T16:12:30.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":48.12,"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001628280-22-005892","document":"wf-form4_164703313587429.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005892/wf-form4_164703313587429.xml","form_type":"4"}},{"id":2338158,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research & Development"}}],"security":"Common Stock","published_at":"2022-03-11T16:12:30.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":21462,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a \"2022 Issuer RSU\") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a \"2022 Issuer RSU\") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-22-005892","document":"wf-form4_164703313587429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005892/wf-form4_164703313587429.xml","form_type":"4"}},{"id":2338157,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research & Development"}}],"security":"Common Stock","published_at":"2022-03-11T16:12:30.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."}],"balance_after":21462,"source":{"system":"sec-edgar","filing":"0001628280-22-005892","document":"wf-form4_164703313587429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005892/wf-form4_164703313587429.xml","form_type":"4"}},{"id":2445260,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research & Development"}}],"security":"Common Stock","published_at":"2022-01-05T17:02:25.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":21462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on February 15, 2023, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of May, August, November, and February. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":36462,"source":{"system":"sec-edgar","filing":"0001628280-22-000342","document":"wf-form4_164142012159914.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022000342/wf-form4_164142012159914.xml","form_type":"4"}},{"id":2600952,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research & Development"}}],"security":"Employee Performance Restricted Stock Unit","published_at":"2021-08-17T08:30:55.000Z","date":"2021-08-15","kind":"grant","acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Employee Performance Restricted Stock Unit (\"PRSU\") represents a contingent right to receive shares of Arena's common stock, which shares shall vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the performance period from August 15, 2021, through March 14, 2024 (the \"Performance Period\") and satisfaction of a continuing service requirement. The reporting person was granted a \"target\" number of PRSUs equal to 50% of the number reported in Column 5. This Form 4 reports the \"maximum\" number of PRSUs, which equals 200% of \"target\" PRSUs, in order to reflect the maximum number of common shares issuable to the reporting person pursuant to the PRSUs."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."}],"balance_after":15200,"derivative":{"expiration_date":"2024-03-14","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001628280-21-017169","document":"wf-form4_162920343662236.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021017169/wf-form4_162920343662236.xml","form_type":"4"}},{"id":2600951,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research & Development"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-08-17T08:30:55.000Z","date":"2021-08-15","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four years, with 25% of the shares subject to the option vesting on August 15, 2022, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":90000,"derivative":{"exercise_price":48.12,"expiration_date":"2028-08-15","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001628280-21-017169","document":"wf-form4_162920343662236.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021017169/wf-form4_162920343662236.xml","form_type":"4"}},{"id":2600950,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":95574,"kind":"person","name":"Manion Douglas J.","position":1,"cik":"0001875875","reported_name":"Manion Douglas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research & Development"}}],"security":"Common Stock","published_at":"2021-08-17T08:30:55.000Z","date":"2021-08-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on August 15, 2022, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of November, February, May, and August. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001628280-21-017169","document":"wf-form4_162920343662236.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021017169/wf-form4_162920343662236.xml","form_type":"4"}}]}